Veracyte (VCYT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Veracyte (VCYT) is Neutral.

The composite score behind that read is +0.10, weighing +0.16 of bullish evidence against -0.13 bearish.

Veracyte last closed at $45.23, +3.74% on the session.

Against the IVW growth benchmark the position is +2.94% over the forecast window.

The read is built from 15 underlying insights — 12 bullish and 3 bearish.

Agreement across those insights is 80%.

Veracyte has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Veracyte in the 28th percentile on valuation and the 56th percentile on return on equity, where 100 is best.

Veracyte is classified under Health Care / Biotechnology, with a market capitalisation of $3.51B.

StockMap tracks Veracyte as the 61st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Veracyte ranks 44th of 381 in the group, against a group median of -0.08.